1. Home
  2. ADCT
  3. ADCT News

Latest ADC Therapeutics SA (ADCT) News on September 17, 2025

Owning 30% shares,hedge funds owners seem interested in ADC Therapeutics SA (NYSE:ADCT),
ADCT

Simply Wall St.

5 days ago

Owning 30% shares,hedge funds owners seem interested in ADC Therapeutics SA (NYSE:ADCT),

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)
ADCT

PR Newswire

3 months ago

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

ADCT

MT Newswires

3 months ago

ADC Therapeutics to Cut 30% of Workforce, Shutter UK Site

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028
ADCT

PR Newswire

3 months ago

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
ADCT

PR Newswire

3 months ago

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

PR Newswire

3 months ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

AbbVie’s ADC win shows how pharma can break through in solid tumors
ADCT

Pharma Voice

4 months ago

AbbVie’s ADC win shows how pharma can break through in solid tumors

ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data
ADCT

Clinical Trials Arena

4 months ago

ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data

ADC Therapeutics to Present at Upcoming Investor Conferences
ADCT

PR Newswire

4 months ago

ADC Therapeutics to Present at Upcoming Investor Conferences

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
ADCT

Zacks

4 months ago

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
ADCT

PR Newswire

4 months ago

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)
ADCT

PR Newswire

4 months ago

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings
ADCT

GuruFocus.com

4 months ago

What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings

Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
ADCT

Zacks

4 months ago

Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025
ADCT

PR Newswire

4 months ago

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates
ADCT

Zacks

5 months ago

Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates

AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
ADCT

Zacks

5 months ago

AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates

Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ADCT

Zacks

5 months ago

Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ADCT

Zacks

5 months ago

ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025
ADCT

PR Newswire

5 months ago

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

PR Newswire

6 months ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
ADCT

PR Newswire

6 months ago

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

ADCT

GuruFocus.com

6 months ago

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ...

ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
ADCT

Simply Wall St.

6 months ago

ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates
ADCT

Zacks

6 months ago

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update
ADCT

PR Newswire

6 months ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
ADCT

PR Newswire

6 months ago

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025
ADCT

PR Newswire

6 months ago

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
ADCT

Zacks

7 months ago

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
ADCT

Zacks

7 months ago

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

PR Newswire

7 months ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
ADCT

PR Newswire

8 months ago

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

PR Newswire

8 months ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Is ADC Therapeutics SA (NYSE:ADCT) Worth US$2.0 Based On Its Intrinsic Value?
ADCT

Simply Wall St.

8 months ago

Is ADC Therapeutics SA (NYSE:ADCT) Worth US$2.0 Based On Its Intrinsic Value?

ADCT

MT Newswires

9 months ago

Update: ADC Shares Rise After Company Completes Enrollment in Late-Stage Zynlonta Combination Trial

ADCT

MT Newswires

9 months ago

ADC Completes Enrollment in Late-Stage Zynlonta Combination Trial

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma
ADCT

PR Newswire

9 months ago

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
ADCT

PR Newswire

9 months ago

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
ADCT

PR Newswire

9 months ago

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

ADCT

MT Newswires

9 months ago

Top Midday Gainers

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
ADCT

PR Newswire

9 months ago

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

PR Newswire

9 months ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ...
ADCT

GuruFocus.com

10 months ago

BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ...

ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations
ADCT

Simply Wall St.

10 months ago

ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why
ADCT

Benzinga

10 months ago

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
ADCT

Zacks

10 months ago

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update
ADCT

PR Newswire

10 months ago

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates
ADCT

Zacks

10 months ago

Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates

What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings
ADCT

GuruFocus.com

10 months ago

What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
ADCT

PR Newswire

10 months ago

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics to Present at November Investor Conferences
ADCT

PR Newswire

10 months ago

ADC Therapeutics to Present at November Investor Conferences

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

PR Newswire

a year ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
ADCT

Zacks

a year ago

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
ADCT

PR Newswire

a year ago

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

Institutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT)
ADCT

Simply Wall St.

a year ago

Institutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT)

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Present at Upcoming Investor Conferences
ADCT

GlobeNewswire

a year ago

ADC Therapeutics to Present at Upcoming Investor Conferences

ADC Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
ADCT

Simply Wall St.

a year ago

ADC Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
ADCT

Zacks

a year ago

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
ADCT

Zacks

a year ago

Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
ADCT

GlobeNewswire

a year ago

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
ADCT

GlobeNewswire

a year ago

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics SA (NYSE:ADCT) Shares Could Be 50% Below Their Intrinsic Value Estimate
ADCT

Simply Wall St.

a year ago

ADC Therapeutics SA (NYSE:ADCT) Shares Could Be 50% Below Their Intrinsic Value Estimate

ADCT

MT Newswires

a year ago

ADC Therapeutics to Join Russell 3000 Index

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADCT

MT Newswires

a year ago

Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
ADCT

GlobeNewswire

a year ago

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
ADCT

GlobeNewswire

a year ago

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

ADC Therapeutics First Quarter 2024 Earnings: In Line With Expectations
ADCT

Simply Wall St.

a year ago

ADC Therapeutics First Quarter 2024 Earnings: In Line With Expectations

Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)
ADCT

GuruFocus.com

a year ago

Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT)

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
ADCT

GlobeNewswire

a year ago

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

ADC Therapeutics SA (NYSE:ADCT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
ADCT

Simply Wall St.

a year ago

ADC Therapeutics SA (NYSE:ADCT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript
ADCT

Insider Monkey

a year ago

ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript

ADCT

MT Newswires

a year ago

HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating

ADCT

MT Newswires

a year ago

ADC Therapeutics Launches $105 Million Offering; Shares Up 2% Pre-Bell

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
ADCT

Zacks

a year ago

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates

ADCT

MT Newswires

a year ago

ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
ADCT

GlobeNewswire

a year ago

ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
ADCT

GlobeNewswire

a year ago

ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADCT

GlobeNewswire

a year ago

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results
ADCT

Simply Wall St.

2 years ago

US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results

ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript
ADCT

Insider Monkey

2 years ago

ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript

ADCT

Thomson Reuters StreetEvents

2 years ago

Q4 2023 ADC Therapeutics SA Earnings Call

ADCT

GuruFocus.com

2 years ago

ADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic Reset

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADCT

Zacks

2 years ago

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
ADCT

GlobeNewswire

2 years ago

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?
ADCT

Zacks

2 years ago

Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?

Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
ADCT

Zacks

2 years ago

Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates

ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
ADCT

GlobeNewswire

2 years ago

ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit

ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
ADCT

GlobeNewswire

2 years ago

ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024

Share on Social Networks: